Schematy leczenia wysiękowej postaci AMD – wady i zalety

• Authors: Anna Święch-Zubilewicz , Joanna Dolar-Szczasny

Title variants

EN

Treating wet form of AMD – pros and cons

• Languages of publication: PL

Abstracts

PL

Terapia anty-VEGF jest obecnie standardem w przypadku wysiękowej postaci AMD. Stosowane leki to: ranibizumab (Lucentis), aflibercept (Eylea) oraz bewacyzumab (Avastin). Ten ostatni w okulistyce podawany jest off-label. Schematy leczenia są różne. Leki można stosować według sztywnego schematu, w zależności od potrzeby (pro re nata) lub w schemacie treat and extend.

EN

Anti-VEGF treatment is a gold standard in exudative AMD. Three drugs are currently used: ranibizumab (Lucentis), aflibercept (Eylea) and off-label bevacizumab (Avastin). Different treatment regimen are used: fixed scheduled treatment, pro re nata and treat and extend.

Keywords

EN

AMD; inhibitory VEGF

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OphthaTherapy
• Year: 2016
• Volume: 3
• Issue: 1
• Pages: 32-36

Contributors

author

Anna Święch-Zubilewicz

• Klinika Chirurgii Siatkówki i Ciała Szklistego, Uniwersytet Medyczny w Lublinie

author

Joanna Dolar-Szczasny

• Klinika Chirurgii Siatkówki i Ciała Szklistego, Uniwersytet Medyczny w Lublinie

References

• 1. Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0,5 mg or 2,0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013; 120: 1046-1056.
• 2. CATT Research Group, Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364(20): 189.
• 3. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010; 117: 2134-2140.
• 4. Holz FG, Amoaku W, Donate J, et al. Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age- -Related Macular Degeneration: The SUSTAIN Study. Ophthalmology 2011; 118: 663-671.
• 5. Klein R, Klein BE, Tomany SC, et al. Ten-year incidence of age-related maculopathy and smoking and drinking: The Beaver Dam Eye Study. Am J Epidemiol 2002; 156: 589-598.
• 6. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148(1): 43-58.
• 7. Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verterporfin plus Ranibizumab for Choroidal Neovascularisation in Age- -Related Macular Degeneration. Twelve-month MONT BLANC Study Results. Ophthalmology 2012; 119(5): 992-1000.
• 8. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119: 1388-1398.
• 9. Muether PS, Hermann MM, Viebahn U, et al. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab. Ophthalmology 2012; 119: 2082-2086.
• 10. Pascolini JD, Mariott SP. Global estimates of visual impairment: 2010. Br J Ophthalmol 2012; 96(5): 614-618.
• 11. Richard G, Monés J, Wolf S, et al. Scheduled versus Pro Re Nata Dosing in the VIEW Trials. Ophthalmology 2015; 122: 2497-2503.
• 12. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
• 13. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014; 121: 192-201.
• 14. Wong TI, Li X, Su X, et al. The Number and Distribution of People with Age-Related Macular Degeneration Worldwide. ARVO 2013: 220-00065.
• 15. Wykoff CC, Croft DE, Brown DM, et al. Prospective Trial of Treat-and Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration. Ophthalmology 2015; 122: 2514-2522.

• Document Type: article